We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$855M
AUM Growth
-$19.9M
Cap. Flow
-$111M
Cap. Flow %
-12.98%
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$11.2M
2
ABMD
Abiomed Inc
ABMD
+$9.03M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.67M
4
EXAS
Exact Sciences
EXAS
+$8.51M
5
MGNX icon
MacroGenics
MGNX
+$7.35M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.1M
2
INCY icon
Incyte
INCY
+$13.5M
3
CELG
Celgene Corp
CELG
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$12.4M
5
EXEL icon
Exelixis
EXEL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.64%
2 Technology 0.15%
3 Energy 0.14%
4 Financials 0.1%
5 Communication Services 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DPLO
51
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$6.99M 0.82%
1,203,405
– –
DERM
52
DELISTED
Dermira, Inc.
DERM
$6.78M 0.79%
+500,329
New +$4.17M
REGN icon
53
Regeneron Pharmaceuticals
REGN
$80.8B
$6.57M 0.77%
16,000
-1,000
-6% -$412K
CELG
54
DELISTED
Celgene Corp
CELG
$6.2M 0.73%
65,698
-150,000
-70% -$13.1M
CHRS icon
55
Coherus Oncology
CHRS
$196M
$6.15M 0.72%
451,131
+130,000
+40% +$1.73M
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$750M
$5.82M 0.68%
226,494
– –
EW icon
57
Edwards Lifesciences
EW
$51.7B
$5.09M 0.6%
79,755
-120,000
-60% -$6.85M
VRAY
58
DELISTED
ViewRay, Inc.
VRAY
$4.91M 0.57%
664,023
– –
ABBV icon
59
AbbVie
ABBV
$435B
$4.83M 0.57%
60,000
-102,415
-63% -$8.38M
ABEO icon
60
Abeona Therapeutics
ABEO
$413M
$4.78M 0.56%
25,965
– –
ALKS icon
61
Alkermes
ALKS
$8.25B
$4.39M 0.51%
120,399
-54,000
-31% -$1.78M
MDCO
62
DELISTED
Medicines Co
MDCO
$3.63M 0.43%
130,000
-5,000
-4% -$118K
GTHX
63
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.52M 0.41%
212,169
+39,349
+23% +$746K
MDGL icon
64
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.41M 0.4%
+27,225
New +$3.38M
RARX
65
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.36M 0.39%
+150,000
New +$3.22M
AIMT
66
DELISTED
Aimmune Therapeutics
AIMT
$3.33M 0.39%
+149,201
New +$3.51M
XLRN
67
DELISTED
Acceleron Pharma
XLRN
$3.26M 0.38%
+70,000
New +$3.07M
RVNC
68
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.04M 0.36%
193,181
– –
NSTG
69
DELISTED
NanoString Technologies, Inc.
NSTG
$2.87M 0.34%
+120,000
New +$2.76M
QGEN icon
70
Qiagen
QGEN
$8.72B
$2.44M 0.28%
+56,583
New +$2.28M
DVAX
71
DELISTED
Dynavax Technologies
DVAX
$2.08M 0.24%
+285,000
New +$2.79M
FLXN
72
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.46M 0.17%
117,265
-389,700
-77% -$5.21M
PVLA
73
Palvella Therapeutics
PVLA
$2.27B
$1M 0.12%
3,750
– –
ACHN
74
DELISTED
Achillion Pharmaceuticals
ACHN
$822K 0.1%
277,800
-125,000
-31% -$307K
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$734K 0.09%
+59,205
New +$662K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rhenman & Partners Asset Management held 101 positions worth $855M, down 2.3% from $875M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $111M in Q1 2019, closing 8 positions and reducing 38 holdings. Its most notable exit was Biogen, an estimated $18.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Technology and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Exact Sciences worth $8.66M.

  • Rhenman & Partners Asset Management's largest Q1 2019 buy was Exact Sciences: 100,000 shares worth $8.66M.
  • Rhenman & Partners Asset Management added most to LivaNova in Q1 2019, an estimated $11.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2019 reduction was Incyte, cutting an estimated $13.5M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q1 2019, selling an estimated $18.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $855M portfolio in Q1 2019.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 8 in Q1 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 2.3% quarter-over-quarter to $855M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.